THE INITIAL TREATMENT RESULTS OF 6 PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR AND ALK CONCURRENT MUTATIONS, AT THE CENTRAL LUNG HOSPITAL
DOI:
https://doi.org/10.59459/1859-1655/JMM.293Từ khóa:
Lung cancer, EGFR, ALK, concurrent mutations, targeted therapyTóm tắt
Purpose: Evaluate the initial treatment results of non-small cell lung cancer with EGFR and ALK concurrent mutations.
Subjects and methods: A prospective study, non-controlled description, and longitudinal follow-up of 6 patients with stage IIIB-IV non-small cell lung cancer, with EGFR and ALK concurrent mutations, at the National Lung Hospital, from January 2022 to July 2023.
Results: The average age of patients was 65.5 years, the male/female gender ratio was 5/1, and the proportion of patients who smoked was 83.3%. Patients were mainly admitted to the hospital due to symptoms of cough (100%), chest pain (50.0%), and dyspnea (33.3%); the majority of patients with stage IV cancer (83.3%); all patients had adenocarcinoma (100%). The average disease-free survival time was 11.36 months. The common unwanted effects were mainly skin rash (83.3%) and diarrhea (66.7%). Elevated liver enzymes and renal failure occurred in the group of patients using a combination of EGFR-TKIs and ALK-TKIs and were the reasons for discontinuation of ALK-TKIs.
Tài liệu tham khảo
Shi Y, Au J.S, Thongprasert S et al (2014), “A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non - small - cell lung cancer of adenocarcinoma histology (PIONEER)”, J Thorac Oncol, (9), 154-162.
Mao Y, Wu S (2017), “ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma”, Onco Targets Ther, 2017;10:3399-3404.
Yang J.J, Zhang X.C, Su J et al (2014), “Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation”, Clin Cancer Res, 2014; 20:1383-1392.
Shaw A.T, Yeap B.Y (2009), “Mino-Kenudson M, Digumarthy SR et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK”, J Clin Oncol, 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10. PMID: 19667264; PMCID: PMC2744268.
Yoon H.Y, Ryu J.S, Sim Y.S, Kim D, Lee S.Y, Choi J, Park S, Ryu Y.J, Lee J.H, Chang J.H (2020), “Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study”, PLoS One, 2020 Feb 13; 15 (2):e0228925. doi: 10.1371/journal.pone.0228925. PMID: 32053675; PMCID: PMC7018076.
Élia Cipriano, Helena Magalhães, Catarina Tavares, João Pinto, Luís Cirnes, Fernanda Estevinho (2021), “Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma - a case report and a literature review”, Porto Biomed. J, 6:1.
Dagogo-Jack I, Rooney M, Lin J.J, Nagy R.J, Yeap B.Y, Hubbeling H, Chin E, Ackil J, Farago A.F, Hata A.N, Lennerz J.K, Gainor J.F, Lanman R.B, Shaw A.T (2019), “Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity”, Clin Cancer Res, 2019 Nov 15; 25 (22): 6662-6670. doi: 10.1158/1078-0432.CCR-19-1436. Epub 2019 Jul 29. PMID: 31358542; PMCID: PMC6858956.
Wang L, Wang W (2021), “Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non - small cell lung cancer (Review)”, Oncol Rep, 2021 Jan; 45 (1): 13-28. doi: 10.3892/or.2020.7851.
Tải xuống
Đã Xuất bản
Cách trích dẫn
Số
Chuyên mục
Chấp nhận đăng 03-01-2024
Ngày xuất bản 28-02-2024
